B cells as under-appreciated mediators of non-auto-immune inflammatory disease

Cytokine

Volumn 50, Issue 3, 2010, Pages 234-242

  Nikolajczyk, Barbara S ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic inflammation; Cytokines; Human B cells; Periodontal disease; Type 2 diabetes

Indexed keywords

B LYMPHOCYTE ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MITOXANTRONE; MYELOID DIFFERENTIATION FACTOR 88; OSTEOCLAST DIFFERENTIATION FACTOR; RITUXIMAB; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANTIBODY PRODUCTION; AUTOIMMUNITY; B LYMPHOCYTE; CD4 CD8 RATIO; CELL FUNCTION; CHRONIC INFLAMMATION; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; HUMAN; IMMUNOCOMPETENT CELL; LYMPHOCYTE DEPLETION; MEMORY CELL; MONOCYTE; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOCLAST; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TH1 CELL; ULCERATIVE COLITIS; VIRUS REACTIVATION;

AUTOIMMUNITY; B-LYMPHOCYTES; CYTOKINES; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; PERIODONTAL DISEASES;

HARNESS;

EID: 77952543791     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.02.022     Document Type: Review

References (135)

1. Salliot C., Dougados M., Gossec L. Risk of serious infections during Rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009, 68:25-32.
2. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2673-2677.
3. Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., Isenberg D.A. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007, 66:1259-1262.
4. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., et al. B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
5. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009, 9:393-407.
6. El Fassi D., Nielsen C.H., Kjeldsen J., Clemmensen O., Hegedus L. Ulcerative colitis following B lymphocyte depletion with Rituximab in a patient with Graves' disease. Gut 2008, 57:714-715.
7. Dass S., Vital E.M., Emery P. Development of psoriasis after B cell depletion with Rituximab. Arthritis Rheum 2007, 56:2715-2718.
8. Yanaba K., Bouaziz J.D., Matsushita T., Magro C.M., St Clair E.W., Tedder T.F. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008, 223:284-299.
9. D'Aiuto F., Graziani F., Tete S., Gabriele M., Tonetti M.S. Periodontitis: from local infection to systemic diseases. Int J Immunopathol Pharmacol 2005, 18:1-12.
10. Stump C.S., Clark S.E., Sowers J.R. Oxidative stress in insulin-resistant conditions: cardiovascular implications. Treat Endocrinol 2005, 4:343-351.
11. Preshaw PM, Foster N, Taylor JJ. Cross-susceptibility between periodontal disease and type 2 diabetes mellitus: an immunobiological perspective. Periodontol 2000 2007;45: 138-157.
12. Tsai C., Hayes C., Taylor G.W. Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Community Dent Oral Epidemiol 2002, 30:182-192.
13. Salvi G.E., Beck J.D., Offenbacher S. PGE2, IL-1 beta, and TNF-alpha responses in diabetics as modifiers of periodontal disease expression. Ann Periodontol 1998, 3:40-50.
14. Wen Y., Gu J., Li S.L., Reddy M.A., Natarajan R., Nadler J.L. Elevated glucose and diabetes promote interleukin-12 cytokine gene expression in mouse macrophages. Endocrinology 2006, 147:2518-2525.
15. Giulietti A., Stoffels K., Decallonne B., Overbergh L., Mathieu C. Monocytic expression behavior of cytokines in diabetic patients upon inflammatory stimulation. Ann N Y Acad Sci 2004, 1037:74-78.
16. Foss-Freitas M.C., Foss N.T., Donadi E.A., Foss M.C. In vitro TNF-alpha and IL-6 production by adherent peripheral blood mononuclear cells obtained from type 1 and type 2 diabetic patients evaluated according to the metabolic control. Ann N Y Acad Sci 2006, 1079:177-180.
17. Sherry C.L., O'Connor J.C., Kramer J.M., Freund G.G. Augmented lipopolysaccharide-induced TNF-alpha production by peritoneal macrophages in type 2 diabetic mice is dependent on elevated glucose and requires p38 MAPK. J Immunol 2007, 178:663-670.
18. Takeichi O., Haber J., Kawai T., Smith D.J., Moro I., Taubman M.A. Cytokine profiles of T-lymphocytes from gingival tissues with pathological pocketing. J Dent Res 2000, 79:1548-1555.
19. Stephens J.W., Hurel S.J., Lowe G.D., Rumley A., Humphries S.E. Association between plasma IL-6, the IL6 -174G>C gene variant and the metabolic syndrome in type 2 diabetes mellitus. Mol Genet Metab 2006, 90:422-428.
20. Wara-Aswapati N., Boch J.A., Auron P.E. Activation of interleukin 1beta gene transcription by human cytomegalovirus: molecular mechanisms and relevance to periodontitis. Oral Microbiol Immunol 2003, 18:67-71.
21. Mealey B.L., Oates T.W. Diabetes mellitus and periodontal diseases. J Periodontol 2006, 77:1289-1303.
22. Engebretson S., Chertog R., Nichols A., Hey-Hadavi J., Celenti R., Grbic J. Plasma levels of tumour necrosis factor-alpha in patients with chronic periodontitis and type 2 diabetes. J Clin Periodontol 2007, 34:18-24.
23. Zhou Q., Leeman S.E., Amar S. Signaling mechanisms involved in altered function of macrophages from diet-induced obese mice affect immune responses. Proc Natl Acad Sci USA 2009, 106:10740-10745.
24. Naguib G., Al-Mashat H., Desta T., Graves D.T. Diabetes prolongs the inflammatory response to a bacterial stimulus through cytokine dysregulation. J Invest Dermatol 2004, 123:87-92.
25. Kantarci A., Oyaizu K., Van Dyke T.E. Neutrophil-mediated tissue injury in periodontal disease pathogenesis: findings from localized aggressive periodontitis. J Periodontol 2003, 74:66-75.
26. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
27. Alabdulkarim M., Bissada N., Al-Zahrani M., Ficara A., Siegel B. Alveolar bone loss in obese subjects. J Int Acad Periodontol 2005, 7:34-38.
28. Pond C.M. Adipose tissue and the immune system. Prostaglandins Leukot Essent Fatty Acids 2005, 73:17-30.
29. Genco R.J., Grossi S.G., Ho A., Nishimura F., Murayama Y. A proposed model linking inflammation to obesity, diabetes, and periodontal infections. J Periodontol 2005, 76:2075-2084.
30. Iacopino A.M. Periodontitis and diabetes interrelationships: role of inflammation. Ann Periodontol 2001, 6:125-137.
31. Loos B.G., Craandijk J., Hoek F.J., Wertheim-van Dillen P.M., van der Velden U. Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. J Periodontol 2000, 71:1528-1534.
32. Noack B., Genco R.J., Trevisan M., Grossi S., Zambon J.J., De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol 2001, 72:1221-1227.
33. Offenbacher S., Beck J.D. A perspective on the potential cardioprotective benefits of periodontal therapy. Am Heart J 2005, 149:950-954.
34. Beck J., Garcia R., Heiss G., Vokonas P.S., Offenbacher S. Periodontal disease and cardiovascular disease. J Periodontol 1996, 67:1123-1137.
35. Ford P.J., Yamazaki K., Seymour G.J. Cardiovascular and oral disease interactions: what is the evidence?. Prim Dent Care 2007, 14:59-66.
36. Spranger J., Kroke A., Mohlig M., Hoffmann K., Bergmann M.M., Ristow M., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52:812-817.
37. Mealey B.L., Rethman M.P. Periodontal disease and diabetes mellitus bidirectional relationship. Dent Today 2003, 22:107-113.
38. Mahanonda R., Sa-Ard-Iam N., Yongvanitchit K., Wisetchang M., Ishikawa I., Nagasawa T., et al. Upregulation of co-stimulatory molecule expression and dendritic cell marker (CD83) on B cells in periodontal disease. J Periodontal Res 2002, 37:177-183.
39. Deshpande R.G., Khan M.B., Genco C.A. Invasion of aortic and heart endothelial cells by Porphyromonas gingivalis. Infect Immun 1998, 66:5337-5343.
40. Haraszthy V.I., Zambon J.J., Trevisan M., Zeid M., Genco R.J. Identification of periodontal pathogens in atheromatous plaques. J Periodontol 2000, 71:1554-1560.
41. Pickup J.C., Crook M.A. Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia 1998, 41:1241-1248.
42. Soyka L.F., Haessler H.A., Crawford J.D. Altered composition and lipolysis of adipose tissue from gold thioglucose obese mice. Am J Physiol 1969, 217:1088-1093.
43. Matsuzawa Y., Shimomura I., Nakamura T., Keno Y., Tokunaga K. Pathophysiology and pathogenesis of visceral fat obesity. Diabetes Res Clin Pract 1994, 24(Suppl):S111-S116.
44. Duffaut C., Galitzky J., Lafontan M., Bouloumie A. Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem Biophys Res Commun 2009, 384:482-485.
45. Ruprecht C.R., Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006, 36:810-816.
46. Rhodes J. Receptor for monomeric IgM on guinea-pig splenic macrophages. Nature 1973, 243:527-528.
47. Messner R.P., Jelinek J. Receptors for human gamma G globulin on human neutrophils. J Clin Invest 1970, 49:2165-2171.
48. Goldstein I.M., Roos D., Kaplan H.B., Weissmann G. Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis. J Clin Invest 1975, 56:1155-1163.
49. Page R.C., Schroeder H.E. Pathogenesis of inflammatory periodontal disease a summary of current work. Lab Invest 1976, 34:235-249.
50. Reinhardt R.A., Bolton R.W., McDonald T.L., DuBois L.M., Kaldahl W.B. In situ lymphocyte subpopulations from active versus stable periodontal sites. J Periodontol 1988, 59:656-670.
51. Berglundh T, Donati M, Zitzmann N. B cells in periodontitis: friends or enemies? Periodontol 2000 2007;45: 51-66.
52. Okada H., Kida T., Yamagami H. Identification and distribution of immunocompetent cells in inflamed gingiva of human chronic periodontitis. Infect Immun 1983, 41:365-374.
53. Berglundh T., Donati M. Aspects of adaptive host response in periodontitis. J Clin Periodontol 2005, 32(Suppl 6):87-107.
54. Takahashi K., Moughal N.A., Mooney J., Kinane D.F. Kappa light chain mRNA bearing plasma cells are predominant in periodontitis lesions. J Periodontal Res 1996, 31:256-259.
55. Freedman A.S., Freeman G., Whitman J., Segil J., Daley J., Levine H., et al. Expression and regulation of CD5 on in vitro activated human B cells. Eur J Immunol 1989, 19:849-855.
56. Freedman A.S., Freeman G., Whitman J., Segil J., Daley J., Nadler L.M. Studies of in vitro activated CD5+ B cells. Blood 1989, 73:202-208.
57. Berglundh T., Liljenberg B., Tarkowski A., Lindhe J. The presence of local and circulating autoreactive B cells in patients with advanced periodontitis. J Clin Periodontol 2002, 29:281-286.
58. Donati M., Liljenberg B., Zitzmann N.U., Berglundh T. B-1a cells and plasma cells in periodontitis lesions. J Periodontal Res 2009, 44:683-688.
59. Sims G.P., Ettinger R., Shirota Y., Yarboro C.H., Illei G.G., Lipsky P.E. Identification and characterization of circulating human transitional B cells. Blood 2005, 105:4390-4398.
60. Han X., Kawai T., Eastcott J.W., Taubman M.A. Bacterial-responsive B lymphocytes induce periodontal bone resorption. J Immunol 2006, 176:625-631.
61. Durali D., de Herve M.G., Giron-Michel J., Azzarone B., Delfraissy J.F., Taoufik Y. In human B cells, IL-12 triggers a cascade of molecular events similar to Th1 commitment. Blood 2003, 102:4084-4089.
62. Harris D.P., Haynes L., Sayles P.C., Duso D.K., Eaton S.M., Lepak N.M., et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000, 1:475-482.
63. Lund F.E., Garvy B.A., Randall T.D., Harris D.P. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005, 8:25-54.
64. Anusaksathien O., Singh G., Matthews N., Dolby A.E. Autoimmunity to collagen in adult periodontal disease: immunoglobulin classes in sera and tissue. J Periodontal Res 1992, 27:55-61.
65. De-Gennaro L.A., Lopes J.D., Mariano M. Autoantibodies directed to extracellular matrix components in patients with different clinical forms of periodontitis. J Periodontol 2006, 77:2025-2030.
66. Mouton C., Hammond P.G., Slots J., Genco R.J. Serum antibodies to oral Bacteroides asaccharolyticus (Bacteroides gingivalis): relationship to age and periondontal disease. Infect Immun 1981, 31:182-192.
67. Hou L., Sasakj H., Stashenko P. B-Cell deficiency predisposes mice to disseminating anaerobic infections: protection by passive antibody transfer. Infect Immun 2000, 68:5645-5651.
68. Graves D.T., Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol 2003, 74:391-401.
69. Yamaguchi M., Ukai T., Kaneko T., Yoshinaga M., Yokoyama M., Ozaki Y., et al. T cells are able to promote lipopolysaccharide-induced bone resorption in mice in the absence of B cells. J Periodontal Res 2008, 43:549-555.
70. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
71. Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005, 11:183-190.
72. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
73. Laharrague P., Fontanilles A.M., Tkaczuk J., Corberand J.X., Penicaud L., Casteilla L. Inflammatory/haematopoietic cytokine production by human bone marrow adipocytes. Eur Cytokine Netw 2000, 11:634-639.
74. Solinas G., Vilcu C., Neels J.G., Bandyopadhyay G.K., Luo J.L., Naugler W., et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab 2007, 6:386-397.
75. Arkan M.C., Hevener A.L., Greten F.R., Maeda S., Li Z.W., Long J.M., et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005, 11:191-198.
76. Winer S., Chan Y., Paltser G., Truong D., Tsui H., Bahrami J., et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009, 15:921-929.
77. Feuerer M., Herrero L., Cipolletta D., Naaz A., Wong J., Nayer A., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009, 15:930-939.
78. Nishimura S., Manabe I., Nagasaki M., Eto K., Yamashita H., Ohsugi M., et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009, 15:914-920.
79. Mizoguchi A., Bhan A.K. A case for regulatory B cells. J Immunol 2006, 176:705-710.
80. Yanaba K., Bouaziz J.D., Haas K.M., Poe J.C., Fujimoto M., Tedder T.F. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008, 28:639-650.
81. Yanaba K., Bouaziz J.D., Matsushita T., Tsubata T., Tedder T.F. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 2009, 182:7459-7472.
82. Fredrikson G.N., Anand D.V., Hopkins D., Corder R., Alm R., Bengtsson E., et al. Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia 2009, 52:1426-1433.
83. Zimering M.B., Pan Z. Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. J Clin Endocrinol Metab 2009, 94:2171-2177.
84. Hempel P., Karczewski P., Kohnert K.D., Raabe J., Lemke B., Kunze R., et al. Sera from patients with type 2 diabetes contain agonistic autoantibodies against G protein-coupled receptors. Scand J Immunol 2009, 70:159-160.
85. Wenzel K., Haase H., Wallukat G., Derer W., Bartel S., Homuth V., et al. Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension. PLoS One 2008, 3:e3742.
86. Ganley-Leal L.M., Liu X., Wetzler L.M. Toll-like receptor 2-mediated human B cell differentiation. Clin Immunol 2006, 120:272-284.
87. Duddy M.E., Alter A., Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation?. J Immunol 2004, 172:3422-3427.
88. Jagannathan M., Hasturk H., Liang Y., Shin H., Hetzel J.T., Kantarci A., et al. TLR cross-talk specifically regulates cytokine production by b cells from chronic inflammatory disease patients. J Immunol 2009, 183:7461-7470.
89. Evans J.G., Chavez-Rueda K.A., Eddaoudi A., Meyer-Bahlburg A., Rawlings D.J., Ehrenstein M.R., et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007, 178:7868-7878.
90. Tian J., Zekzer D., Hanssen L., Lu Y., Olcott A., Kaufman D.L. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol 2001, 167:1081-1089.
91. Mizoguchi A., Mizoguchi E., Takedatsu H., Blumberg R.S., Bhan A.K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002, 16:219-230.
92. Anolik J.H., Looney R.J., Lund F.E., Randall T.D., Sanz I. Insights into the heterogeneity of human B cells diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009, [Epub ahead of print].
93. Duddy M., Niino M., Adatia F., Hebert S., Freedman M., Atkins H., et al. Bar-or a distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007, 178:6092-6099.
94. Roll P., Palanichamy A., Kneitz C., Dorner T., Tony H.P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006, 54:2377-2386.
95. Anolik J.H., Barnard J., Owen T., Zheng B., Kemshetti S., Looney R.J., et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007, 56:3044-3056.
96. Anolik J.H., Friedberg J.W., Zheng B., Barnard J., Owen T., Cushing E., et al. B cell reconstitution after Rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007, 122:139-145.
97. Blair P.A., Norena L.Y., Flores-Borja F., Rawlings D.J., Isenberg D.A., Ehrenstein M.R., Mauri C. CD19(+)CD24(hi)CD38(hi) B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients. Immunity 2010, 32:129-140.
98. Fillatreau S., Sweenie C.H., McGeachy M.J., Gray D., Anderton S.M. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3:944-950.
99. Mauri C., Gray D., Mushtaq N., Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003, 197:489-501.
100. Lampropoulou V., Hoehlig K., Roch T., Neves P., Calderon Gomez E., Sweenie C.H., et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol 2008, 180:4763-4773.
101. van Exel E., Gussekloo J., de Craen A.J., Frolich M., Bootsma-Van Der Wiel A., Westendorp R.G. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002, 51:1088-1092.
102. Shin H., Zhang Y., Jagannathan M., Hasturk H., Kantarci A., Liu H., et al. B cells from periodontal disease patients express surface Toll-like receptor 4. J Leukoc Biol 2009, 85:648-655.
103. Kubaszek A., Pihlajamaki J., Komarovski V., Lindi V., Lindstrom J., Eriksson J., et al. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 2003, 52:1872-1876.
104. Kristiansen O.P., Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes 2005, 54(Suppl 2):S114-S124.
105. Pickup J.C., Chusney G.D., Thomas S.M., Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000, 67:291-300.
106. Lee H.J., Kang I.K., Chung C.P., Choi S.M. The subgingival microflora and gingival crevicular fluid cytokines in refractory periodontitis. J Clin Periodontol 1995, 22:885-890.
107. Hirose K., Isogai E., Miura H., Ueda I. Levels of Porphyromonas gingivalis Fimbriae and inflammatory cytokines in gingival crevicular fluid from adult human subjects. Microbiol Immunol 1997, 41:21-26.
108. Irwin C.R., Myrillas T.T. The role of IL-6 in the pathogenesis of periodontal disease. Oral Dis 1998, 4:43-47.
109. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., Mier J.W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83:113-118.
110. Wallenius V., Wallenius K., Ahren B., Rudling M., Carlsten H., Dickson S.L., et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002, 8:75-79.
111. Yamazaki K., Nakajima T., Gemmell E., Polak B., Seymour G.J., Hara K. IL-4- and IL-6-producing cells in human periodontal disease tissue. J Oral Pathol Med 1994, 23:347-353.
112. Noronha A.M., Liang Y., Hetzel J.T., Hasturk H., Kantarci A., Stucchi A., et al. Hyperactivated B cells in human inflammatory bowel disease. J Leukoc Biol 2009, 86:1007-1016.
113. Tonetti M.S., Imboden M.A., Gerber L., Lang N.P., Laissue J., Mueller C. Localized expression of mRNA for phagocyte-specific chemotactic cytokines in human periodontal infections. Infect Immun 1994, 62:4005-4014.
114. Tonetti M.S., Imboden M.A., Lang N.P. Neutrophil migration into the gingival sulcus is associated with transepithelial gradients of interleukin-8 and ICAM-1. J Periodontol 1998, 69:1139-1147.
115. Ishihara Y., Nishihara T., Kuroyanagi T., Shirozu N., Yamagishi E., Ohguchi M., et al. Gingival crevicular interleukin-1 and interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites. J Periodontal Res 1997, 32:524-529.
116. Yucel O.O., Berker E., Gariboglu S., Otlu H. Interleukin-11, interleukin-1beta, interleukin-12 and the pathogenesis of inflammatory periodontal diseases. J Clin Periodontol 2008, 35:365-370.
117. Orozco A., Gemmell E., Bickel M., Seymour G.J. Interleukin-1beta, interleukin-12 and interleukin-18 levels in gingival fluid and serum of patients with gingivitis and periodontitis. Oral Microbiol Immunol 2006, 21:256-260.
118. Tsiavou A., Degiannis D., Hatziagelaki E., Koniavitou K., Raptis S.A. Intracellular IFN-gamma production and IL-12 serum levels in latent autoimmune diabetes of adults (LADA) and in type 2 diabetes. J Interferon Cytokine Res 2004, 24:381-387.
119. Pistoia V., Cozzolino F., Rubartelli A., Torcia M., Roncella S., Ferrarini M. In vitro production of interleukin 1 by normal and malignant human B lymphocytes. J Immunol 1986, 136:1688-1692.
120. Zupo S., Perussia B., Baldi L., Corcione A., Dono M., Ferrarini M., et al. Production of granulocyte-macrophage colony-stimulating factor but not IL-3 by normal and neoplastic human B lymphocytes. J Immunol 1992, 148:1423-1430.
121. Tran T.T., Yamamoto Y., Gesta S., Kahn C.R. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab 2008, 7:410-420.
122. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with Rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
123. Fleischmann R.M. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on Rituximab. Semin Arthritis Rheum 2009, 38:265-280.
124. Dai M.S., Chao T.Y., Kao W.Y., Shyu R.Y., Liu T.M. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with Rituximab plus CHOP. Ann Hematol 2004, 83:769-774.
125. Tsutsumi Y., Kanamori H., Mori A., Tanaka J., Asaka M., Imamura M., et al. Reactivation of hepatitis B virus with Rituximab. Expert Opin Drug Saf 2005, 4:599-608.
126. Suzan F., Ammor M., Ribrag V. Fatal reactivation of cytomegalovirus infection after use of Rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001, 345:1000.
127. Bermudez A., Marco F., Conde E., Mazo E., Recio M., Zubizarreta A. Fatal visceral varicella-zoster infection following Rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000, 85:894-895.
128. Ennishi D, Yokoyama M, Terui Y, Takeuchi K, Ikeda K, Tanimoto M, Hatake K. Does Rituximab really induce hepatitis C virus reactivation? J Clin Oncol 2008;26: 4695-6; author reply 4696.
129. Bonavita S., Conforti R., Russo A., Sacco R., Tessitore A., Gallo A., et al. Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and Rituximab. Neurol Sci 2008, 29:37-39.
130. Harris H.E. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with Rituximab. Rheumatology (Oxford) 2008, 47:224-225.
131. Hopfinger G., Plessl A., Grisold W., Klimpfinger M., Hoftberger R., Bernt R., et al. Progressive multifocal leukoencephalopathy after Rituximab in a patient with relapsed follicular lymphoma and low IgG levels and a low CD4+ lymphocyte count. Leuk Lymphoma 2008, 49:2367-2369.
132. Kranick S.M., Mowry E.M., Rosenfeld M.R. Progressive multifocal leukoencephalopathy after Rituximab in a case of non-Hodgkin lymphoma. Neurology 2007, 69:704-706.
133. Steurer M., Clausen J., Gotwald T., Gunsilius E., Stockhammer G., Gastl G., et al. Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation Rituximab. Transplantation 2003, 76:435-436.
134. Yokoyama H., Watanabe T., Maruyama D., Kim S.W., Kobayashi Y., Tobinai K. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during Rituximab-containing chemotherapy: case report and review of the literature. Int J Hematol 2008, 88:443-447.
135. Fleischmann R.M. Progressive multifocal leukoencephalopathy following Rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009, 60:3225-3228.